Is GHK-Cu approved or legal?

GHK-Cu (as Copper Tripeptide-1) is widely used as a cosmetic skincare ingredient. It is not an approved drug for systemic/injectable therapeutic use. Research-grade GHK-Cu is sold for laboratory research only and is not approved for human consumption; legality varies by jurisdiction.

What does the human clinical evidence actually support?

The strongest human evidence is topical: small placebo-controlled facial and eye cream trials show increased collagen, improved skin density/thickness, and reduced fine lines and photodamage over about 12 weeks. Broader tissue-repair, nerve and systemic claims are mostly preclinical.

What is GHK-Cu's half-life and how is it dosed?

Its systemic half-life in humans is not well characterized; endogenous GHK is cleared quickly and declines with age. There is no validated clinical injectable dose. Topical products typically use low concentrations (around 0.05%) applied daily. Any injectable protocols are anecdotal.

Topical use has a strong safety record, with mainly transient redness or mild irritation, and copper levels too low to cause systemic toxicity. Injectable use is less studied; excessive copper intake is a theoretical concern, and long-term human safety data are limited.

Topical or injectable - which is better studied?

Topical is far better studied in humans and is how the cosmetic benefits were demonstrated. Injectable use is popular in communities but lacks controlled human trials and should be considered experimental and research-reference only.

Aesthetic

GHK-Cu

Also known as: Copper Peptide, GHK-Copper, Copper Tripeptide-1, Glycyl-L-histidyl-L-lysine:copper(II)

Copper-binding tripeptide studied mainly topically for collagen synthesis, skin repair and wound healing; human evidence is largely cosmetic.

Last updated July 11, 2026

Reconstitute this peptide Buy GHK-Cu

Overview

GHK-Cu is a naturally occurring copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with copper II) first isolated from human plasma in 1973. Endogenous GHK plasma levels decline with age, falling from roughly 200 ng/mL at age 20 to about 80 ng/mL by age 60, a drop that researchers have linked to reduced regenerative capacity. It is best known as an ingredient in anti-aging skincare under the cosmetic name Copper Tripeptide-1. The strongest human evidence is topical and cosmetic: small placebo-controlled facial-cream and eye-cream trials report increased collagen, improved skin density and thickness, and reductions in fine lines and photodamage over roughly 12 weeks. Much of the broader literature on tissue, nerve and systemic effects is preclinical (animal and in-vitro) or based on gene-expression profiling. Despite popularity in research-peptide communities for injectable and reconstituted use, there is no established systemic dosing protocol from controlled human trials. Injectable use is anecdotal and carries different risk considerations than topical use, including copper handling. GHK-Cu products sold as research material are not approved for human consumption.

How it works

GHK-Cu acts both as a copper-delivery vehicle and as a direct signaling molecule. The peptide binds copper(II) in a configuration that silences copper's redox activity, allowing relatively nontoxic copper transport into cells where it supports cuproenzymes involved in connective-tissue formation and antioxidant defense. Independently of copper transport, gene-profiling studies report that GHK modulates a large fraction of human genes, up- and down-regulating pathways tied to tissue remodeling, the ubiquitin-proteasome system, and inflammation. Functionally it stimulates synthesis of collagen, elastin, glycosaminoglycans, dermatan/chondroitin sulfate and decorin, modulates matrix metalloproteinases and their inhibitors, promotes angiogenesis (biphasic) via VEGF, and attracts immune and endothelial cells to injury sites. It also shows antioxidant activity, reducing iron release from ferritin and inactivating lipid-peroxidation byproducts in preclinical work.

Researched effects

Clinical Increases skin collagen production and improves skin density, thickness and firmness when applied topically
Clinical Reduces appearance of fine lines, wrinkles and photodamage in facial/eye cosmetic creams over ~12 weeks
Preclinical Improves wound re-epithelialization and healing (e.g., post-procedure and ulcer settings)
Preclinical Stimulates angiogenesis, fibroblast activity and glycosaminoglycan/elastin synthesis
Preclinical Supports nerve outgrowth and neurotrophic factor expression
Preclinical Antioxidant and anti-inflammatory tissue-protective effects
Anecdotal Promotes hair growth and follicle health
Anecdotal Improves general skin tone, healing and recovery via injectable/reconstituted use

Evidence levels: Clinical (human trials) · Preclinical (animal/lab) · Anecdotal (community-reported).

Dosing reference

For research reference only — not a recommendation.

Clinical / studied dosing

No established systemic (injected) clinical dosing in humans. Human evidence is topical and cosmetic, where formulations typically contain low concentrations (commonly around 0.05% GHK-Cu in serums/creams) applied daily for ~12 weeks. Reviews have speculated that a systemic therapeutic amount might be on the order of 100-200 mg, but this is an estimate from the literature, not a validated dosing protocol from controlled human trials.

Community-reported dosing (anecdotal)

Anecdotal only - research-reference, not medical advice or instruction. Community sources and some provider guides describe injectable subcutaneous protocols such as ~1 mg/day for the first ~15 days, increasing to ~2 mg/day, run as roughly 30-day-on / 30-day-off cycles, injected into rotating abdominal sites with an insulin syringe. Many users instead apply GHK-Cu topically. These figures are self-reported, not validated by controlled trials, and are listed for research context only.

Half-life: Unknown / not well characterized in humans; endogenous plasma GHK is cleared rapidly and declines with age (~200 ng/mL at 20 to ~80 ng/mL at 60). Topical effects depend on formulation rather than a defined systemic half-life.
Routes: topical, subcutaneous

Safety & side effects

Topical GHK-Cu has a favorable safety record; the most commonly reported effects are transient redness and mild itching or mild irritation, and the copper content in cosmetic products is far too low to cause systemic copper toxicity. Decades of cosmetic use have not produced reports of serious adverse events, but well-powered long-term human trials are lacking. Injectable/reconstituted use carries different and less-characterized risks: dosing errors or excessive copper intake could in principle contribute to copper accumulation, so long-term injectable users are sometimes advised to monitor copper and ceruloplasmin. People with Wilson's disease or other copper-handling disorders should be especially cautious. Research-grade material is not pharmaceutical-grade and is not approved for human use.

Research summary

GHK-Cu is one of the better-studied cosmetic peptides, with a coherent mechanistic story spanning copper delivery and direct gene modulation. The clinical human evidence is real but narrow: it consists mainly of small, often industry-adjacent, placebo-controlled topical trials showing modest but measurable improvements in collagen, skin density and visible aging markers over about three months. These results support its use as a skincare active more than as a systemic therapeutic. The broader and more dramatic claims - wound healing acceleration, nerve regeneration, anti-inflammatory, antioxidant, anti-cancer and lung-tissue effects - rest largely on animal, in-vitro and gene-expression data. This preclinical work is extensive and consistent, but it has not been confirmed by adequately powered human trials, so those benefits should be treated as promising hypotheses rather than established outcomes. Injectable and reconstituted use is popular in research-peptide communities but is not backed by controlled human dosing studies; reported protocols are anecdotal. Overall, GHK-Cu appears low-risk topically and is biologically plausible systemically, but the evidence gap between cosmetic trials and the wider therapeutic claims is significant. Claims should be qualified accordingly, and any human use framed as outside approved indications.

FAQ

Is GHK-Cu approved or legal?: GHK-Cu (as Copper Tripeptide-1) is widely used as a cosmetic skincare ingredient. It is not an approved drug for systemic/injectable therapeutic use. Research-grade GHK-Cu is sold for laboratory research only and is not approved for human consumption; legality varies by jurisdiction.
What does the human clinical evidence actually support?: The strongest human evidence is topical: small placebo-controlled facial and eye cream trials show increased collagen, improved skin density/thickness, and reduced fine lines and photodamage over about 12 weeks. Broader tissue-repair, nerve and systemic claims are mostly preclinical.
What is GHK-Cu's half-life and how is it dosed?: Its systemic half-life in humans is not well characterized; endogenous GHK is cleared quickly and declines with age. There is no validated clinical injectable dose. Topical products typically use low concentrations (around 0.05%) applied daily. Any injectable protocols are anecdotal.
Is GHK-Cu safe?: Topical use has a strong safety record, with mainly transient redness or mild irritation, and copper levels too low to cause systemic toxicity. Injectable use is less studied; excessive copper intake is a theoretical concern, and long-term human safety data are limited.
Topical or injectable - which is better studied?: Topical is far better studied in humans and is how the cosmetic benefits were demonstrated. Injectable use is popular in communities but lacks controlled human trials and should be considered experimental and research-reference only.

References

All content is for research and educational use only and is not medical advice. Products are sold for laboratory research only and are not for human consumption.